» Articles » PMID: 18322170

Cutting Edge: the Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

Overview
Journal J Immunol
Date 2008 Mar 7
PMID 18322170
Citations 227
Authors
Affiliations
Soon will be listed here.
Abstract

Memory B (B(MEM)) cells and long-lived bone marrow plasma cells (BM-PCs) persist within local environmental survival niches that afford cellular longevity. However, the factors supporting B(MEM) cell survival within the secondary lymphoid organs and allowing BM-PC persistence in the bone marrow remain poorly characterized. We report herein that long-lived B(MEM) cell survival and function are completely independent of BAFF (B cell-activating factor of the TNF family) or APRIL (a proliferation-inducing ligand). Thus, B(MEM) cells represent the only mature B2 lineage subset whose survival is independent of these ligands. We have previously shown that the TNFR family member receptor BCMA (B cell maturation Ag) is a critical survival receptor for BM-PC survival in vivo. We identify in this study the ligands critical for BM-PC survival and show that either BAFF or APRIL supports the survival of BM-PCs in vivo. These data define the BAFF/APRIL-dependent and -independent components of long-lived humoral immunity.

Citing Articles

A genome wide CRISPR screen reveals novel determinants of long-lived plasma cell secretory capacity.

DSouza L, Young J, Coffman H, Petrow Jr E, Petrow E, Bhattacharya D bioRxiv. 2025; .

PMID: 40060628 PMC: 11888458. DOI: 10.1101/2025.02.28.640639.


Survival of Human Bone Marrow Plasma Cells In Vitro Depends on the Support of the Stromal Cells, PI3K, and Canonical NF-kappaB Signaling.

Uyar-Aydin Z, Kadler S, Lauster R, Bartfeld S, Rosowski M Eur J Immunol. 2025; 55(1):e202451358.

PMID: 39777683 PMC: 11708448. DOI: 10.1002/eji.202451358.


CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases.

Vukovic J, Abazovic D, Vucetic D, Medenica S Front Med (Lausanne). 2024; 11:1447147.

PMID: 39450112 PMC: 11500465. DOI: 10.3389/fmed.2024.1447147.


Editorial: IgA nephropathy: a nephrologist's challenge in 2023.

Catapano F, Flossmann O, Del Vecchio L Front Nephrol. 2024; 4:1477350.

PMID: 39323970 PMC: 11422340. DOI: 10.3389/fneph.2024.1477350.


Structure-based humanization of a therapeutic antibody for multiple myeloma.

Marino S, Daumke O J Mol Med (Berl). 2024; 102(9):1151-1161.

PMID: 39052065 PMC: 11358308. DOI: 10.1007/s00109-024-02470-4.